|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.580 USD | -3.01% |
|
+3.61% | -18.10% |
| Capitalization | 1.33B 1.15B 1.07B 1B 1.85B 120B 2.01B 12.56B 4.85B 56.66B 5B 4.9B 207B | P/E ratio 2025 * |
-14.9x | P/E ratio 2026 * | -102x |
|---|---|---|---|---|---|
| Enterprise value | 1.17B 1.01B 945M 881M 1.63B 106B 1.77B 11.05B 4.27B 49.87B 4.4B 4.31B 182B | EV / Sales 2025 * |
0.62x | EV / Sales 2026 * | 0.42x |
| Free-Float |
75.33% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Clover Health Investments, Corp.
| 1 day | -3.01% | ||
| 1 week | +3.61% | ||
| Current month | +3.61% | ||
| 1 month | -1.15% | ||
| 3 months | -6.18% | ||
| 6 months | -15.55% | ||
| Current year | -18.10% |
| 1 week | 2.41 |  | 2.72 |
| 1 month | 2.16 | | 2.72 |
| Current year | 2.12 | | 4.87 |
| 1 year | 2.12 | | 4.87 |
| 3 years | 0.61 | | 4.87 |
| 5 years | 0.61 | | 28.85 |
| 10 years | 0.61 | | 28.85 |
| Manager | Title | Age | Since |
|---|---|---|---|
Andrew Toy
CEO | Chief Executive Officer | 46 | 31/12/2022 |
Peter Kuipers
DFI | Director of Finance/CFO | 53 | 06/05/2024 |
Conrad Wai
CTO | Chief Tech/Sci/R&D Officer | 44 | 27/02/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Vivek Garipalli
CHM | Chairman | 46 | 31/12/2022 |
Andrew Toy
BRD | Director/Board Member | 46 | 31/10/2018 |
William Robinson
BRD | Director/Board Member | 60 | 24/03/2021 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 0.02% | 324 M€ | +10.62% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -3.01% | +3.61% | -23.21% | +116.81% | 1.33B | |
| -0.77% | +0.35% | -39.79% | -38.64% | 300B | |
| -0.31% | -2.22% | -13.45% | -37.41% | 73.51B | |
| -1.11% | -4.27% | -16.48% | -19.48% | 70.91B | |
| +1.91% | +4.92% | -8.48% | -52.80% | 31.01B | |
| -1.31% | -2.54% | -32.45% | -55.38% | 18.84B | |
| +0.86% | +2.43% | -48.52% | -54.75% | 7.81B | |
| +0.77% | +1.77% | +71.64% | +60.38% | 3.91B | |
| -0.54% | -8.91% | +62.74% | -24.89% | 2.07B | |
| -0.17% | -1.03% | -21.87% | - | 388M | |
| Average | -0.37% | -0.70% | -6.99% | -11.80% | 50.95B | |
| Weighted average by Cap. | -0.58% | -0.48% | -29.37% | -36.30% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1.9B 1.64B 1.53B 1.43B 2.64B 171B 2.87B 17.93B 6.92B 80.92B 7.14B 6.99B 296B | 2.62B 2.25B 2.11B 1.97B 3.63B 236B 3.95B 24.69B 9.53B 111B 9.84B 9.63B 407B |
| Net income | -88.48M -76.05M -71.25M -66.41M -123M -7.96B -133M -833M -322M -3.76B -332M -325M -13.75B | -12.48M -10.73M -10.05M -9.37M -17.3M -1.12B -18.82M -118M -45.4M -531M -46.85M -45.85M -1.94B |
| Net Debt | -160M -137M -129M -120M -222M -14.38B -241M -1.51B -581M -6.79B -600M -587M -24.83B | -234M -201M -188M -175M -324M -21.03B -352M -2.2B -850M -9.93B -877M -858M -36.31B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/12/25 | 2.580 $ | -3.01% | 4,010,881 |
| 04/12/25 | 2.660 $ | +1.53% | 4,740,749 |
| 03/12/25 | 2.620 $ | +5.22% | 4,431,408 |
| 02/12/25 | 2.490 $ | -0.40% | 3,065,043 |
| 01/12/25 | 2.500 $ | +0.40% | 5,556,234 |
Delayed Quote Nasdaq, December 05, 2025 at 09:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CLOV Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition